FULLSCREEN > Archive > 2024 > Vol 5, №10 (2024) > Efficacy of fremanezumab in patients with chronic migraine and concomitant depression Efficacy of fremanezumab in patients with chronic migraine and concomitant depression

Background. Migraine is a common chronic disorder that ranks third in the disability-adjusted life years among nervous system disorders. It is well known that migraine is strongly associated with the depression/anxiety disorders; there is overwhelming data suggesting common mechanisms underlying migraine and depression, including involvement of the neurotransmitter systems, such as calcitonin gene-related peptide (CGRP). Aim. Efficacy of fremanezumab in patients with chronic migraine (CM) and concomitant depression. Methods. A total of 48 patients aged 23–57 years with the established diagnosis of CM and depression took part in the study. Fremanezumab in a dose of 225 mg was administered monthly throughout 6 months. Clinical interviewing and headache diary assessment were performed every month, and the Hamilton Depression Inventory (Hamilton Depression Rating Scale) was filled during the first visit, on months 3 and 6. Results. A significant decrease in the headache frequency with the steady increase of effect by month 3 of therapy and the effect persistence by month 6 of therapy is reported in patients with CM and depression. A significant decrease in the depression scores based on the Hamilton Depression Rating Scale is observed. Conclusion. Fremanezumab can be used as one of the first-line drugs for treatment of patients with CM and concomitant depression.